Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

which isn’t a defined concept in UK patent legislation, when it delivers its judgment. The biotech association wants to see a balance struck so that biotech or pharma companies are not unfairly ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Neurizon (ASX:NUZ) has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, ...

As 2025 kicks off there’s lots of activity in the world of IP – particularly in the Biotech and Pharma sectors, writes Marc Wilkinson, Partner with J A Kemp. We at J A Kemp LLP have plenty to talk ...

A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event.

Last year was a surprisingly big one for legal decisions impacting the biotechnology transactions and licensing space. Given that most biotech ...